Reviticell Holdings
- Company typePrivate
- Founded2011
- HeadquartersJacksonville, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Reviticell Holdings firmographics
Firmographics- Name
- Reviticell Holdings
- Website
- https://reviticell.com
- Company type
- Private
- Founded year
- 2011
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Reviticell Holdings industry classification
Industry- Product category
- Regenerative Medicine Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
Keywords
Where Reviticell Holdings is headquartered
LocationHeadquarters
- HQ city
- Jacksonville
- HQ country
- United States
- HQ region
- North America
Markets served
Reviticell Holdings business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
Reviticell Holdings product offering
Product offeringCore offering
Reviticell Holdings develops and supplies Reviticell Kits, described as highly scalable medical devices intended to make regenerative medical procedures more efficient. The kits are positioned as physical medical device products intended for clinical use by healthcare providers performing regenerative therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- Reviticell Kits
Companies that use Reviticell Holdings
Customer profileIdeal customer profiles1 record
Reviticell Holdings technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Reviticell Holdings competitors and assessment
Company assessmentBroad incumbents
- Arthrex: Global orthopedic device leader with the Angel concentrated-BMC/PRP kit family — the closest scaled incumbent addressing the same point-of-care regenerative-kit need Reviticell targets.
- Organogenesis: Public regenerative-medicine company (Apligraf, Dermagraft, NuShield) serving wound care and surgical applications — a broader regenerative-device peer to Reviticell's regenerative-procedure thesis.
- MiMedx: Public regenerative medicine company built on dehydrated amniotic membrane and other tissue platforms used in wound and surgical healing — broad incumbent in the regenerative-device category.
- Vericel: Public regenerative-medicine company behind MACI and Epicel — operates in autologous cell-based regenerative therapies addressing sports medicine and burn applications adjacent to Reviticell's focus.
- Integra LifeSciences: Diversified medical-device platform with a regenerative tissue technologies franchise (Integra dermal regeneration templates) — relevant broader incumbent in regenerative wound and surgical products.
- Smith & Nephew: Global medical-device company with significant wound-care and orthobiologics portfolios that overlap with the regenerative-procedure category Reviticell is targeting.
- Stryker: Large diversified medical-device company with regenerative and sports-medicine offerings (including biologics and platelet-processing kits used in orthopedic surgery).
Direct peers
- Emcyte Corporation (Crown Laboratories): Acquired by Crown Laboratories, Emcyte is best known for point-of-care PRP and cell-concentrate kits used in regenerative procedures — a direct category analogue to the Reviticell Kit concept.
- Regen Lab: Swiss developer of the Cellular Matrix and RegenKit lines for point-of-care preparation of PRP and cell-concentrate therapies; competes in the same 'scalable regenerative kit' niche.
- Isto Biologics: Producer of bone-marrow aspirate concentrate systems and orthobiologic kits used in regenerative orthopedic procedures — overlapping directly with Reviticell's stated value proposition.
Market position
Customer concentration
Reviticell Holdings social profiles
Digital presenceReviticell Holdings financial estimates
Financial estimateRevenue estimate
Valuation estimate
Reviticell Holdings leadership team
Management profileNumber of profiles
Profiles8 records
Reviticell Holdings funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Reviticell Holdings M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Reviticell Holdings
What does Reviticell Holdings do?
Reviticell Holdings develops and supplies Reviticell Kits, described as highly scalable medical devices intended to make regenerative medical procedures more efficient. The kits are positioned as physical medical device products intended for clinical use by healthcare providers performing regenerative therapies.
When was Reviticell Holdings founded?
Reviticell Holdings was founded in 2011. It employs 1 to 10 people.
Where is Reviticell Holdings based?
Reviticell Holdings is headquartered in Jacksonville, United States, in the North America region.
Who are Reviticell Holdings's main competitors?
Broad incumbents on record are Arthrex, Organogenesis, MiMedx, Vericel, Integra LifeSciences, Smith & Nephew and Stryker. Direct peers are Emcyte Corporation (Crown Laboratories), Regen Lab and Isto Biologics.
Does Reviticell Holdings have an API?
No public API is recorded for Reviticell Holdings.
What industry is Reviticell Holdings in?
Reviticell Holdings's product category is Regenerative Medicine Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 339113 and its SIC code is 3841.